Biotechnology

Coultreon Biopharma's strategic hire of Dr. Prista Charuworn signals a major push to advance its novel SIK3 inhibitor in the crowded autoimmune market.

A Boston biotech with Korean roots just went public in Seoul. Its goal: to repair the body's smallest blood vessels, a market Merck has already bet billions on.

A free online calculator for an experimental drug seems trivial. But it reveals the hidden operational layer where scientific breakthroughs are forged.

Beyond beta-blockers, a new class of targeted therapies is revolutionizing hypertrophic cardiomyopathy care, sparking a fierce corporate race for market dominance.

A new 'cell mimic' control from Slingshot Bio promises to eliminate a major source of variability in cellular analysis, streamlining complex research workflows.

A new survey reveals the staggering cost of clinical trial delays, but the real story isn't the numbers—it's the systemic breakdown of a fragmented, manual process.

In a strategic pivot, Skye Bioscience acquires Redx Pharma, creating Fibrx Therapeutics—a new Nasdaq-listed player armed with $125M and a bold plan.

New preclinical data shows NurExone's ExoPTEN protects vital nerve coatings, providing a biological basis for functional recovery in spinal cord injury models.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

As Evaxion prepares its Q2 update, investors watch to see if its AI-Immunology™ platform can deliver the financial and clinical results for long-term value.

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

Fannin Partners secures key grants to advance its Raptamer therapy for a rare pediatric cancer, highlighting a funding model vital for high-risk innovation.

With a new CEO, a leaner budget, and crucial data on the horizon for its brain and obesity drugs, Neumora is navigating a pivotal phase of growth.

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

Caribou Biosciences reports impressive clinical data for its allogeneic CAR-T therapies, but the path to broader patient access hinges on a critical hurdle: funding.

Kyntra Bio's Q2 profit was driven by a one-time accounting gain, masking operating losses. Now, the firm bets its future on two critical Q4 data readouts.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?

With over $1B in cash, Nektar is pushing its novel drug, rezpegaldesleukin, into final trials. It's a high-stakes bet on a new era for autoimmune care.